Found 1 Presentation For Request "computational"
Presentation Topic- New diagnostic tools
Filtered By
- New diagnostic tools
1146P - Closing the target gap: A computational approach to optimizing therapeutic selection for cancer patients
- Mikhail Grushko (Natick, AL, United States of America)
Abstract
Background
While significant progress has been made in developing new therapies for cancer patients, many patients lack treatments that result in favorable outcomes. Existing patient-therapy matching algorithms frequently rely on mutations or other well-studied targets for which limited FDA-approved therapies exist. In contrast, SHEPHERD’s approach, called DELVE, uses computational and mathematical tools informed by transcriptomic data to match therapies with the models, cancers, and specific patients that will be most impacted by drug treatment, regardless of mutational status.
Methods
DELVE leverages bioinformatics, chemoinformatics, proprietary algorithms, deep learning neural networks, random forest classifiers, and other tools to generate transcriptomic-level drug response-resistance signatures. DELVE was deployed to characterize drug response and resistance across thousands of
Results
DELVE was able to correctly classify the highest and lowest responding drug-cell line pairs with 96% sensitivity [CI +/- 0.34%] and 88% specificity [CI +/- 1.71%]. Across published
Conclusions
DELVE is able to predict drug efficacy on cancer models and to correctly select indications for existing therapies, supporting its utility in predicting new indications for cancer therapies. Because the platform can operate on any single transcriptome, it is possible to use this tool to match patients with therapies from which they may benefit without reliance on a previously classified target.
Legal entity responsible for the study
Shepherd Therapeutics.
Funding
Shepherd Therapeutics.
Disclosure
M. Grushko, J. Goldstein, Z. ElSeht, A. Alarcon, M. Samizadeh, Y. Zhu, J. Kaplan, K. Arline: Financial Interests, Personal, Ownership Interest: Shepherd Therapeutics. N. Jones: Financial Interests, Personal, Full or part-time Employment: Shepherd Therapeutics.